Podcasts about Pill

Sarah, Evan, Paul, and Ken look extensively at the dramatic events with ICE and Border Patrol in Minnesota asking questions about the right use of force, the legitimacy of deportations, and whether the two deaths there were justified or preventable. We also look at a suggestion for a national divorce and a breaking story in the Charismatic world involving the downfall of at least one big name.

Patriots, lock and load—@intheMatrixxx and @shadygrooove unleash full throttle on 1-29-26's explosive broadcast, diving deep into Season 8, Episode 019, “President Trump's 10th Cabinet Meeting; Trump Calls Out Black Pill Network,” where Trump's repost of a video spotlighting the Anti-Flynn network's misleading narratives crushes black-pill despair and validates years of calling out the hopium sellers. Jeff and Shannon break down the fiery online clash after Flynn labeled the Trump-shared video "fake," proving the truth hits hard against those peddling defeatism while Trump racks up massive victories in the 10th Cabinet Meeting—from skyrocketing GDP, border shutdowns, plunging gas prices, and healthcare cost slashes to the game-changing John Deere deal bringing excavator manufacturing back home to America thanks to smart tariffs. They spotlight RFK Jr.'s amazing progress pushing health reforms and the shocking "poison candy" intel from Casey DeSantis-led research exposing dangerous arsenic levels in popular brands, urging families to wake up to hidden threats in everyday products. No mainstream spin here—just raw, unfiltered analysis rejecting establishment lies and celebrating the unstoppable America First surge. The truth is learned, never told—the constitution is your weapon—tune in at noon-0-five Eastern LIVE to stand with Trump! MG Show: America First MAGA Podcast & Conservative Talk Show Launched in 2019 and now in Season 8, the MG Show is your go-to source for unfiltered truth on Trump policies, border security, economic nationalism, and exposing globalist psyops. Hosted by Jeffrey Pedersen (@InTheMatrixxx) and Shannon Townsend (@ShadyGrooove), it champions sovereignty, traditional values, and critiques of establishment politics. Tune in weekdays at 12pm ET / 9am PT for patriotic insights strengthening the Republic under President Trump's America First agenda. Hosts - Jeffrey Pedersen (@InTheMatrixxx): Expert in political analysis and exposing hidden agendas, with a focus on Trump's diplomatic wins and media bias. - Shannon Townsend (@ShadyGrooove): Delivers sharp insights on intelligence operations, Constitutional rights, and defenses of Trump's strategies against mainstream critiques. Where to Watch & Listen Catch live episodes or on-demand replays packed with MAGA victories like inflation drops, border awards, Trump pardons, and psyop exposures: - Live Streams: https://rumble.com/mgshow for premium America First content. - Radio: https://mgshow.link/redstate on Red State Talk Radio. - X Live: https://x.com/inthematrixxx for real-time pro-Trump discussions. - Podcasts: Search "MG Show" on PodBean, Apple Podcasts, Pandora, and Amazon Music. - YouTube: Full episodes at https://youtube.com/c/inthematrixxx and https://www.youtube.com/c/TruthForFreedom. Follow for daily pro-Trump alerts: - X: @InTheMatrixxx (https://x.com/inthematrixxx) and @ShadyGrooove (https://x.com/shadygrooove). Support the MG Show Fuel the MAGA movement against establishment lies: - Donate: https://mg.show/support or contribute at https://givesendgo.com/helpmgshow. - Merch: https://merch.mg.show for official gear. - MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow. - Crypto: https://mgshow.link/rumblewallet. All Links Everything MG Show Related: https://linktr.ee/mgshow. MG Show Anthem Get chills with the patriotic track: https://youtu.be/SyfI8_fnCAs

Kentucky braces for a powerful winter storm, a bill extending concealed carry rights to young adults clears the state House, a committee considers the impeachment of a state Supreme Court justice, and Kentucky's Attorney General is looking into mail-order abortion pills.

Pharmaceutical company Apnimed said its pill, AD109, is a simple-to-use once-daily oral drug that could "expand and reshape the treatment landscape." Armed with findings from critical phase 3 clinical trials, the company said within months, it's set to submit the pill for a New Drug Application with the Food and Drug Administration. Covering hundreds of studies on digital media and health effects over the last 20 years, the review’s findings mark a departure from previous thoughts on screen use. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

The Alan Cox Show

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

The Food and Drug Administration on recently approved a pill version of Wegovy, Novo Nordisk's blockbuster weight loss drug. The Wegovy pill, as it's called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in the coming months. Nicolette M. Pace, a Registered Dietician, Chef, & Nutritionist, is here to talk about all this and more!

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sarah, Paul, Cody, and Evan look at the deathbed conversion of Scott Adams, the ongoing immigration chaos in Minneapolis and beyond, whether autonomy is possible or even good, Trump's one-finger salute, and the ongoing gender confusion at the highest levels of our government.

WhoJimmy Ackerson, General Manager of Corralco, ChileRecorded onJuly 24, 2025About CorralcoClick here for a mountain stats overviewLocated in: Curacautín, Araucanía, ChileYear founded: 2003, by Enrique BascurPass affiliations: Indy Pass, Indy+ Pass – 2 days, no blackoutsBase elevation: 4,724 feet (1,440 meters)Summit elevation: 7,874 feet (2,400 meters) top of lifts; 9,400 feet (2,865 meters) hike-toVertical drop: 3,150 feet (960 meters) lift-served; 4,676 feet (1,425 meters) hike-toSkiable acres: 2,475 acres lift served; 4,448 acres (1,800 hectares), including hike-to terrainAverage annual snowfall: 354 inches (899 cm)Trail count: 34Lift count: 7 (1 high-speed quad, 1 double, 5 J-bars)Why I interviewed himThe Andes run the length of South America, 4,300 miles from the southern tip of Argentina north to Venezuela. It is the longest continental mountain range on Earth, nearly six times the length of the Alps and 1,300 miles longer than the Rockies. It is the highest mountain range outside of Asia, topping out at 22,841 feet on Mount Aconcagua, more than a mile higher than the tallest point in the Rockies (14,439-foot Mount Elbert) or Alps (15,772-foot Mont Blanc).So this ought to be one hell of a ski region, right? If the Alps house more than 500 ski areas and the Rockies several hundred, then the Andes ought to at least be in the triple digits?Surprisingly, no. Of the seven nations transected by the Andes, only Argentina and Chile host outdoor, lift-served ski areas. Between the two countries, I'm only able to assemble a list of 37 ski areas, 33 of which skiresort.info categorizes as “temporarily closed” – a designation the site typically reserves for outfits that have not operated over the past several seasons.For skiers hoping to live eternal winter by commuting to the Upside Down each May through October, this roster may be a bit of a record scratch. There just aren't that many ski areas in the Southern Hemisphere. Outside of South America, the balance – another few dozen total - sit in Australia and New Zealand, with scattered novelties such as Afriski lodged at the top of Lesotho. There are probably more ski areas in New England than there are south of the equator.That explains why the U.S.-based multimountain ski passes have been slow to move into the Southern Hemisphere – there isn't much there to move into. Ikon and Mountain Collective each have just one destination on the continent, and it's the same destination: Valle Nevado. Epic offers absolutely nothing in South America.Even with few options, Vail moved south a decade ago with its purchase of Perisher, Australia's largest ski area. That English-speaking nation was a logical first pass frontier, but the five Kangaroo resorts claimed by the Epic and Ikon passes are by far the five largest in the country, and they're a 45-year flight from America. New Zealand is similarly remote, with more but generally less-developed ski areas, and Ikon has established a small presence there.But South America remains mostly wide open, despite its obvious appeal to North Americans: the majesty of the Andes, the novelty of summer skiing, and direct flights with no major timezone hopping required. Mountain Capital Partners has dropped anchor in Chile, purchasing Valle Nevado in 2023, neighboring La Parva the following year, and bidding for also-neighboring El Colorado in 2025 (that sale is pending regulatory review).But perhaps it's time for a broader invasion. Last March, Indy Pass added Corralco as its first South American – and first Southern Hemisphere – ski area. That, as Ackerson and I discuss in the podcast, could be just the start of Indy's ambitions for a continent-spanning (or at least, Argentina- and Chile-spanning) resort network.So this is a good time to start getting to know Chilean skiing. And Ackerson, longtime head of the Chilean Ski Areas Association, former leader of Chilean giants Portillo and Valle Nevado, and a Connecticut-born transplant who has been living the upside-down life for more than 50 years, is probably better suited than anyone on the planet to give us that intro.What we talked aboutReverse ski seasons; why Corralco draws (and retains) so much more snow than any other ski area in Chile; no snowmaking; Corralco as training ground for national ski teams; the logistics of moving a high-speed quad from Holiday Valley, New York to the Chilean Andes; rebuilding a lift as a longer machine; how that lift transformed Corralco; new lift, new alignment; the business impact of replacing a double chair with a high-speed quad; how a dude who grew up in Connecticut with non-skiing parents ended up running a ski area in South America; Chile's allure; Portillo; Chilean skiing past and present; Corralco's founding and evolution; shrinking South American ski areas; Mountain Capital Partners (MCP) buying four more ski areas in Chile after purchasing Valle Nevado in 2023 and La Parva in 2024; the Americans are coming; why La Parva, Valle Nevado, and El Colorado “have to be consolidated” for the benefit of future skiing in Chile; MCP's impact on Chilean skiing so far; “the culture is very different here” both on the hill and off; MCP's challenges as they settle into Chilean skiing; why Corralco joined Indy Pass; a potential Indy Pass network in South America; and getting to Corralco from the U.S., from airplane to access road – “we have no switchbacks.”What I got wrong* In the intro, I said that it was the “heart of ski season in South America.” This was true when we recorded this conversation in July 2025. It's not true in January 2026, when the Chilean ski season is long over.* I said the highest peak in Chile only received a few inches of snow per year and didn't retain it, but I couldn't remember the name of the peak – it is 22,615-foot Ojos del Salado.* I gave new stats for Corralco's high-speed quad, but did not mention where those stats came from – my source was skiresort.info, which catalogues a 4,921-foot length and 1,148-foot vertical drop for the lift, both substantially longer than the 4,230-foot length and 688-foot vertical rise that Lift Blog documents for the antecedent Mardi Gras lift at Holiday Valley, New York. We discuss the logistics and mechanics of moving this machine from North to South America and extending it in the pod. Here are a few pics of this machine I took in New York in January 2022:Podcast NotesOn Corralco's evolving footprintCorralco is a new-ish ski area, at least insofar as public access goes. The 2008 trailmap shows a modest vertical drop served by surface lifts:But growth has been rapid, and by 2022, the ski area resembled modern Corralco, which is now an international training center for athletes:On Camp Jewel, ConnecticutAckerson learned to ski on a two-tow bump called Camp Jewell, a YMCA center in Connecticut. NELSAP has some fun info on this defunct ski area, including photos of what's left of the lifts.On Sigi GrottendorderAckerson's conduit to South American skiing came in the form of Austrian-born Sigi Grottendorfer, who led the ski schools at both Sugarbush, Vermont and Portillo, Chile. He passed away in 2023 – The Valley Reporter ran an obituary with more info on Grottendorfer's expansive and colorful life.On Chile “five years after the coup had occurred”We reference past political instability in Chile, referring to the 1973 coup that launched the military dictatorship of the notorious Augusto Pinochet. The nation transitioned back to democracy in 1990 and is considered safe and stable for tourists by the U.S. State Department.On PortilloWe discuss Portillo, a Chilean ski area whose capacity limits and weeklong ski-and-stay packages result in Windham-is-private-style (it's not) confusion. Skiers can visit Portillo on a day pass. Lift tickets are all of $68. Still, the hotel experience is, by all accounts, pretty rad. Here's the bump:On previous podcastsWe mention a few previous podcast guests who had parallels to Ackerson's story. Bogus Basin GM Brad Wilson also left skiing for several years to run a non-ski resort:Longtime Valle Nevado GM Ricardo Margolis appeared on this podcast in 2023:On the shrinking of Volcán Osorno and PillánI won't reset the entire history here, but I broke down the slow shrinkage of Volcán Osorno and Pillán ski areas when Mountain Capital Partners bid to purchase them last year:On Kamori Kankō buying HeavenlyFor a brief period, Japanese company Kamori Kankō owned Steamboat and Heavenly. The company sold both to American Skiing Company in 1997, and they eventually split owners, with Heavenly joining Vail's roster in 2002, and Steamboat now part of Alterra by way of Intrawest. Today, Kamori Kankō appears to operate five ski areas in Japan, all in Hokkaido, most notably Epic Pass partner Rusutsu:On MCP's free season passes for kids 12 and underOne pretty cool thing that Mountain Capital Partners has brought to Chile from its U.S. HQ is free season passes for kids 12 and under. It's pretty incredible:On Sugarbush Ackerson worked for a long time at Sugarbush, an Alterra staple and one of the best overall ski areas in New England. It's a fully modern resort, with the exception of the knockout Castle Rock terrain, which still spins a double chair on all-natural snow:On skiing El ColoradoWe discuss the insane, switchbacking access road up to El Colorado/La Parva/Valle Nevado from Santiago:The route up to Corralco is far more suited to mortals:The Storm explores the world of lift-served skiing year-round. Join us. Get full access to The Storm Skiing Journal and Podcast at www.stormskiing.com/subscribe

What if the secret to a good life isn't just what you achieve but how deeply you love? Drawing on wisdom from Aristotle, Jesus and modern social psychology, philosopher Meghan Sullivan offers tips on how to expand your capacity for love, even in the face of our modern challenges. Hosted on Acast. See acast.com/privacy for more information.

1-14 Adam and Jordana 11a hour

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses a a sleep apnea pill and if she thinks it will be approved by the FDA.

Your healthcare provider runs the tests, orders the meds, and sends you home to "manage" your condition. Meanwhile, there's something backed by reliable research that could potentially reverse it. Something simple, and nobody told you. But WHY?Not because it doesn't work. This has reversed cancers, MS, lupus, type 2 diabetes, autoimmune diseases, chronic headaches, stubborn weight, crushing fatigue, joint pain, brain fog, high blood pressure, elevated cholesterol. The list keeps going.So why the silence? That's what we're exposing in this episode. The real reasons this stays buried. What Jarrod and I discovered at 40 that changed everything. Something natural you can start today if your body has become the bottleneck to your calling.We're handing you the truth so you can break through.What if you run out of time before you reach your full potential? What if your body steals the years you need to complete your assignment?This is THE fight of our generation. Christian leaders are linking arms, refusing to let our bodies become the weapon our enemy uses to stop us. Satan is going to hate this episode, which is the perfect reason to press play.It's time for purpose-driven leaders and Kingdom entrepreneurs to rise up and bring "His Kingdom Come" to this earth….together!

In this episode, we explore the science behind NAD, cellular energy, and aging with Tru Niagen CEO Robert Fried—and you can try it yourself with 20% off at truniagen.com using code GENIUS20.15 Daily Steps to Lose Weight and Prevent Disease PDF: https://bit.ly/46XTn8f - Get my FREE eBook now!Subscribe to The Genius Life on YouTube! - http://youtube.com/maxlugavereWatch my new documentary Little Empty Boxes - https://www.maxlugavere.com/filmThis episode is proudly sponsored by:If you're curious about supporting cellular energy and healthy aging, check out Tru Niagen at truniagen.com and use code GENIUS20 for 20% off.Timeline Nutrition makes MitoPure—a purified form of urolithin A, which provides powerful mitochondrial support for increased energy and longevity. Go to http://timelinenutrition.com/genius for 10% off of your order. If you've ever had one of those nights where your brain won't shut off, CBDistillery's Enhanced Deep Sleep Gummies are the low-dose THC/CBN/CBD combo I personally use to help wind down without feeling groggy. Save 25% at CBDistillery.com with code MAX.

In this important episode, I break down the newly FDA-approved Wegovy pill and what it means for obesity treatment. The first oral GLP-1 medication for obesity has arrived, offering a needle-free alternative to weekly injections. This development could transform access for patients who've avoided treatment due to injection hesitation, cost barriers, or preference for daily pill routines. Tune in to learn what the Wegovy pill is, how it works, and why it represents a major step forward in giving patients more options for sustainable weight loss. Sign up for the Back on Track: Setting the Vision for your health Masterclass:  https://drshellymd.kit.com/ecc62a0638   Episode Highlights: How the Wegovy pill works as a daily medication vs. weekly injections The science behind GLP-1 receptor agonists and appetite regulation Clinical data showing approximately 13.6% body weight reduction Overcoming injection hesitation—a major barrier to treatment adherence Proper dosing: daily pill on empty stomach with specific timing requirements Common side effects and important black box warnings to know Affordable self-pay pricing: starting at $149/month through NovoCare pharmacy program Why more options mean better care for chronic disease management   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to discuss a study that looks at the correlation between caffeine intake and the risk for diabetes, the new federal dietary guidelines, and how the Wegovy pill is different from the injection. He also talks about the most important heart health habit […]

Plus: Andreessen Horowitz raises over $15 billion across several funds. And LG Electronics expects to post a quarterly operating loss for the first time since 2016. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hour 2 of A&G features... New jobs numbers & spending Philadelphia sheriff threat & programs the US has pulled out of Running Venezuela, Russia/Ukraine war & Iran Sober party girls, cigarettes on the rise & Maduro's hoodie See omnystudio.com/listener for privacy information.

In this January 9 episode of The Daily Herold, Jon Herold is joined by Ghost for an extended conversation focused on developments surrounding Venezuela, Nicolás Maduro's removal, and what recent statements from President Trump suggest about continuity of government, interim leadership, and U.S. intentions. Ghost shares analysis of constitutional orders signed before Maduro's departure, media mischaracterizations of regime change, and how Colombia, cartels, and regional military activity factor into the broader picture. Jon and Ghost review Trump's comments on oil, prisoners, sanctions, and upcoming meetings with Colombian leadership, while questioning common assumptions about U.S. intervention and long-term targets. The latter portion of the show shifts to domestic discussion, including a White House video on historical resistance, federal fraud enforcement announcements, and a live chat-driven conversation on “black pilling,” dissent, and the role of criticism within the Badlands community. The episode closes with additional headlines, audience interaction, and programming updates.

The first highly effective oral GLP-1 weight loss medication is here. In this episode, Lisa Oldson, MD breaks down the FDA-approved PILL version of semaglutide (oral Wegovy), how GLP-1 receptor agonists work for weight loss, expected results, side effects, cost, and who qualifies for these medications. She also discusses why weight loss medication is not “cheating,” how GLP-1 oral meds compare to injectables, and the World Health Organization's new recommendations supporting long-term use of GLP-1 medications for excess weight. If you're curious about GLP-1 weight loss pills, obesity treatment, and evidence-based approaches to long-term health, this episode is for you.You'll learn:What's new about ORAL (pill form) WegovyWhy weight loss medication is not cheatingHow the brain regulates weightHow GLP-1 medications workMedication + lifestyle: not either / orThanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Hour 2 of A&G features... New jobs numbers & spending Philadelphia sheriff threat & programs the US has pulled out of Running Venezuela, Russia/Ukraine war & Iran Sober party girls, cigarettes on the rise & Maduro's hoodie See omnystudio.com/listener for privacy information.

Get the stories from today's show in THE STACK: https://justinbarclay.comJoin Justin in the MAHA revolution - http://HealthWithJustin.comProTech Heating and Cooling - http://ProTechGR.com New gear is here! Check out the latest in the Justin Store: https://justinbarclay.com/storeKirk Elliott PHD - FREE consultation on wealth conservation - http://GoldWithJustin.comTry Cue Streaming for just $2 / day and help support the good guys https://justinbarclay.com/cueUp to 80% OFF! Use promo code JUSTIN http://MyPillow.com/JustinPatriots are making the Switch! What if we could start voting with our dollars too? http://SwitchWithJustin.com

Dan Bongino declares total war on black-pillers and grifters (many amplified by paid bot armies) trying to sabotage MAGA from within, especially as midterms loom. Marjorie Taylor Greene's explosive final day in Congress — is the backlash real or bot-farm manufactured division? Geopolitics: U.S. moves on Venezuelan oil (seizures, handovers, resource plays) with Greenland's strategic riches in the crosshairs. And the ultimate red-pill twist — how superior intelligence can drive you to madness in a world overrun by AI bot farms pushing propaganda, defeatism, and fake engagement to break minds and movements. No holds barred — truth over comfort.

Seattle is desperately trying to backtrack after reports it was moving towards drug decriminalization. Just like Minnesota, Washington is dealing with its own allegations of fraud. There’s now a pill version of the popular weight loss drug Wegovy. // LongForm: GUEST: Let's Go Washington's Brian Heywood on what's next now that two citizen intitiatives have received enough signatures to make it on the ballot. // Quick Hit: An update on allegations that Hilton hotels were denying reservations to ICE agents.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Season eight of the MG Show opens with the hosts announcing their return and outlining how the program is broadcasting across multiple platforms while rallying supporters. They set the tone by thanking listeners and framing the episode as a continuation of long-running investigations into media and political networks. The hosts discuss a widely shared post by Dan Bongino and use it to launch a critique of what they call "black-pill" operators and grifters within the conservative movement. They highlight Kash Patel as a key figure, praise actions attributed to him and others in the FBI, and contrast those developments with influencers and networks they say have harmed the movement. On the January 6 anniversary, the show revisits contested narratives about that day, focusing on alleged connections involving Michael Flynn, Roger Stone, Proud Boys and Oath Keepers, and testimony they say points to delays in deploying the National Guard. The hosts frame these topics as part of a broader discussion about accountability, optics, and inside actors. The episode also examines the Reawakened Tour, InfoWars-associated personalities, Patrick Byrne's admissions, and claims of infiltration and manipulation across platforms. The hosts argue that military-grade psychological operations are influencing public perception and driving division, and they urge listeners to examine actions over rhetoric. The show closes with calls to support the program through donations and platform engagement, a summary assertion that Americans should think independently, and an appeal to continue the campaign for what the hosts describe as restoring the original vision of the country.

This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims. Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered. Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention. This episode isn't anti-pharma or pharma-friendly. It's patient-first. And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once? Episode Timestamps 00:00 — Why this first episode of 2026 matters 02:10 — Hair found in Wegovy pens and why patients notice hypocrisy 06:15 — Arrowhead trial headlines vs. what the data actually shows 11:40 — Why tirzepatide dosing and trial design matter 17:30 — What INHBE targeting may actually be good for (and what it's not) 21:45 — Sponsor: SHED and access pathways for obesity care 25:10 — Oral Wegovy officially launches: what's different this time 30:20 — How the Wegovy pill works and why bioavailability matters 35:40 — Pricing, telehealth, Costco, and direct-to-consumer access 41:50 — Why pills lower barriers for millions of patients 46:10 — Manufacturing quality, Catalent, and FDA citations 52:30 — Why safety arguments against compounding are being scrutinized 58:40 — Zooming out: access, accountability, and patient trust 1:02:00 — Final thoughts and what to watch next Topics Covered GLP-1 trial hype vs. real-world context Phase 1 data limitations and headline inflation Tirzepatide dosing and misleading comparisons Oral Wegovy vs. compounded oral semaglutide GLP-1 pill pricing and insurance implications Direct-to-consumer pharma and telehealth disruption Manufacturing quality and FDA oversight Compounding pharmacies and healthcare system resilience Patient trust, transparency, and credibility in obesity medicine Useful Links & Resources On The Pen Links & Advocacy: https://otplinks.com Sponsor – SHED (use code OTP25): https://tryshed.com FDA Drug Safety & Recalls: https://www.fda.gov/drugs Follow On The Pen: YouTube: https://youtube.com/@onthepen Substack: https://onthepen.substack.com Support the Show If this episode helped you better understand what's really happening in obesity medicine: Leave a 5-star rating and review Hit Subscribe so you don't miss future episodes Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube Patients deserve clarity. That's what we're here for. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you don't want to inject yourself with a weight loss drug, now you have the chance to take a pill. 

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

In this edition of Nina’s What’s Trending, three wildly different stories spark big reactions—and even bigger opinions. A major shift in the weight loss world has people questioning safety, access, and who these new options are really for. At the same time, a viral streaming series with sky-high ratings is dividing viewers in a way no one saw coming. And just when you think you’ve heard it all, one simple YouTube upload proves you really can make serious money doing almost nothing at all. Nina's What's Trending is your daily dose of the hottest headlines, viral moments, and must-know stories from The Jubal Show! From celebrity gossip and pop culture buzz to breaking news and weird internet trends, Nina’s got you covered with everything trending right now. She delivers it with wit, energy, and a touch of humor. Stay in the know and never miss a beat—because if it’s trending, Nina’s talking about it! This is just a tiny piece of The Jubal Show. You can find every podcast we have, including the full show every weekday right here…➡︎ https://thejubalshow.com/podcasts The Jubal Show is everywhere, and also these places: Website ➡︎ https://thejubalshow.com Instagram ➡︎ https://instagram.com/thejubalshow X/Twitter ➡︎ https://twitter.com/thejubalshow Tiktok ➡︎ https://www.tiktok.com/@the.jubal.show Facebook ➡︎ https://facebook.com/thejubalshow YouTube ➡︎ https://www.youtube.com/@JubalFresh Support the show: https://the-jubal-show.beehiiv.com/subscribeSee omnystudio.com/listener for privacy information.

AP correspondent Julie Walker reports abortion stays legal in Wyoming.

The ousted Venezuelan leader and his wife had their first federal court appearance today. The Department of Health and Human Services is planning a major change to childhood vaccination schedule. Minnesota governor Tim Walz announced he won't run for reelection. The Pentagon is punishing Democratic Senator Mark Kelly for his recent remarks. Plus, a new, cheaper weight-loss drug hit the market. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Wegovy's first weight-loss pill is now available nationwide. Also, experts predict 2026 health trends will focus on expanded GLP-1 use, AI-powered wearable devices, and the “food as medicine” approach. Plus, author Adam Grant discusses how to unlock your hidden potential for greater success. And, NBC turns 100 in 2026, celebrating a century of news, entertainment, and memories. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This is one of the most important conversations happening in women's health right now. For decades, hormonal birth control has been prescribed as the default solution for everything from acne to cramps — often without any explanation of long-term consequences. Today, we unpack the truth: how the pill affects your body, your hormones, your fertility, your mental health, and even your future relationships.This episode dives deep into the science, the lived experiences, and the lesser-known side effects women face after years on synthetic hormones. If you've ever taken the pill, considered it, struggled to get pregnant post-pill, or wondered why your body changed after stopping — this is essential listening.Joining me in this conversation is Elizabeth Katzman. She is a Functional Diagnostic Nutrition Practitioner and the founder of Strong Choices. She specializes in helping women in their reproductive and midlife years uncover the root causes of hormone imbalances, fatigue, stubborn weight gain, and gut issues—often tied to years on hormonal birth control. Using advanced lab testing, functional protocols, and personalized strategies, Elizabeth empowers women to reclaim their energy, strength, and clarity.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Market update for Monday January 5, 2026Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode:U.S. oil stocks rally as investors bet on long-term upside in VenezuelaNovo Nordisk launches the first-ever GLP-1 weight-loss pill in the U.S.Mobileye jumps after landing a major U.S. automaker for self-driving techComcast slides as its cable spinoff Versant officially begins tradingCES kicks off in Vegas as tech giants test consumer demand for AI hardware

Most men think ED is just a performance issue. It's not. It's one of the earliest warning signs of cardiovascular decline and it often appears years before chest pain, shortness of breath, or heart attack symptoms.Thank you to our sponsors! -EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off.-GOT MOLD? | Go to http://gotmold.com/shop and use DAVE10 to save 10% and see what's in your air.Chapters00:00 - The “Legal Blue Pill” Myth & Hidden Danger00:57 - What ED Actually Is (Not the Commercial Version)01:45 - Circulation, Arteries & the Real Root Cause03:27 - The Problem with Relying on ED Pills05:03 - Treat ED as a Cardiovascular Symptom05:55 - Patterns That Reveal Vascular Decline07:10 - The ED–Heart Attack Countdown Window08:14 - How To Fix This Problem10:10 - Microdosing Cialis for Vascular Support10:45 - Aspirin as Another Option11:15 - Lifestyle Drivers of Vascular Damage & Solutions13:15 - Movement, Walking & Circulation Basics13:40 - The Mitochondria–Erection Connection15:00 - Recharging Mitochondria16:02 - Chronic Inflammation: The Silent Culprit17:17 - Smoking, Vaping, Obesity & Diabetes18:30 - How To Reduce InflammationResources: • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Connect with Dave Asprey!Website: https://daveasprey.comTikTok: https://www.tiktok.com/@daveaspreyofficialInstagram: https://www.instagram.com/dave.asprey/Facebook: https://www.facebook.com/Daveaspreyofficial/X: https://x.com/daveaspreyYouTube: https://www.youtube.com/c/daveaspreybprThe Human Upgrade Podcast: Instagram: https://www.instagram.com/TheHumanUpgradePodcast/ Facebook: https://m.facebook.com/Thehumanupgrade/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Evan and Adam Ellwanger are joined by first-time guest Paul Fortunato to take a look at the Somali day care story taking the social media world by storm, whether demons can live in AI, and two stories of Islam and violence.

The NBA loves a fairytale ending — legends riding off into the sunset with one last ring. But the reality is harsher: aging championship stars can become a “poison pill” for franchises, locking teams into oversized salaries, outdated roster-building, and stalled player development.In this episode of On The Ball, Ric Bucher breaks down why it's so difficult to break up a title-winning core — and why the Los Angeles Lakers and Golden State Warriors are the latest examples of teams paying the price for loyalty while still selling championship expectations.Ric also explains why the best organizations make the cold-blooded pivot before the clock strikes midnight, the role fans and media play in keeping “one more run” alive, and how teams end up stuck when the window closes but the payroll doesn't.00:00:35 – Where to find Ric (FS1/Fox Sports Radio) + new book on being coachable 00:01:18 – Holiday delay + why Christmas Day set up this episode 00:01:49 – The “poison pill” problem: aging champions and marquee teams 00:02:14 – Why breaking up a championship core is so hard 00:03:11 – History lesson: teams that waited too long to turn the page 00:03:38 – Loyalty is fine… if you're honest about expectations 00:05:02 – The hidden cost: money, roles, roster, coaching, and marketing built around stars 00:06:02 – Why “contend + develop” usually doesn't work (Warriors example) 00:06:48 – What real transition looks like (Wade → LeBron, Duncan → Kawhi) 00:07:52 – Fans, connection, and the business of keeping “the guy” 00:09:45 – Media vs fan reality: why we get it twisted about “upgrades” 00:11:31 – Booker/Suns as the blueprint for “glimmer of hope” economics 00:15:26 – The “glimmer” sidebar + players who sell hope without June basketball 00:16:53 – Why it's different when the star actually won a ring 00:17:41 – The ruthless move: trade the star before midnight 00:18:42 – Recent examples of teams doubling down on aging stars 00:19:12 – Bill Walsh trading Joe Montana: the blueprint 00:20:19 – Which current GMs will actually make the hard pivot? 00:21:52 – Teams that missed the window: Lakers/Warriors/Clippers (and why it matters now) 00:22:39 – Lakers roster-building problem around Luka + payroll realities 00:23:20 – Warriors payroll trap: Steph/Jimmy/Draymond math 00:25:17 – Why re-signing Draymond locked in the old identity 00:25:50 – Klay nostalgia vs reality + the real mistake 00:26:22 – Wrap-up + teaser on tanking/competition solutions next episodeFollow Ric Bucher: X / Instagram / Threads / Bluesky: @RicBucher #NBA #Lakers #Warriors #LeBronJames #StephenCurry #JimmyButler #DraymondGreen #NBATalk #NBAAnalysis #OnTheBall #RicBucher #UnitedWeCastSupport this show http://supporter.acast.com/bucher-and-friends. Hosted on Acast. See acast.com/privacy for more information.

Headlines: – Welcome To Mo News (02:00) – AAA Expecting A Record-Setting Year For Holiday Travel (04:30) – Record-Breaking Warmth Chases Away White Christmas Dreams (06:00) – Justice Department Releases New Batch Of Documents In Epstein Investigation (07:00) – U.S. Economic Growth Surged in Third Quarter of 2025 (14:15) – FDA Approves New Wegovy Weight Loss Pill (16:20) – Supreme Court Refuses to Allow National Guard Deployment in Chicago (18:20) – How to Track Santa Claus This Christmas Eve With NORAD's 2025 Tracker (20:30) – What We're Watching, Reading, Eating (23:30) Thanks To Our Sponsors:  – LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Aura Frames -  $35 off best-selling Carver Mat frames | Promo Code: MONEWS – Monarch - 50% off your first year | Promo Code: MONEWS

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

The news to know for Tuesday, December 23, 2025! We're talking about the next push to expand the immigration crackdown in the U.S. in the new year. And why dozens of American diplomats were just removed from their jobs. Also: what to expect from a new "Trump class" of Navy battleships. Plus: approval for a promising new weight-loss pill that's like Ozempic, controversy surrounding a 60 Minutes episode that hasn't aired, and new artwork from the elusive street artist Banksy—that seems a bit different from much of his other work. Those stories and even more news to know in about 10 minutes!    Join us every Mon-Fri for more daily news roundups!  See sources: https://www.theNewsWorthy.com/shownotes Become an INSIDER to get AD-FREE episodes here: https://www.theNewsWorthy.com/insider Get The NewsWorthy MERCH here: https://thenewsworthy.dashery.com/ Sponsors: You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/NEWSWORTHY and using code NEWSWORTHY at checkout. To advertise on our podcast, please reach out to ad-sales@libsyn.com    

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

The S&P 500 closing at a fresh record high, as commodities come along for the ride. If the metal moves in Gold, Silver, and Copper can keep rocking into the new year, and how this morning's strong GDP report will impact the Fed's next rate decision. Plus Shares of Novo Nordisk on the move as the pharma company's weight loss pill gets approved by the FDA. How the decision can tip the scales for Novo, and what one analyst sees in store for the weight loss drug space.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.